SUBSCRIBE
SUBSCRIBE
News   Drug Development

AVANIR Pharmaceuticals Announces Last Patient Enrolled In Neuropathic Pain Phase III Trial With Zenvia

November 15, 2006 | 
1 min read
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced today that the Company has enrolled the targeted number of patients needed to assess the efficacy endpoint in its ongoing Zenvia Phase III painful diabetic neuropathy trial.
Clinical research Phase III
MORE ON THIS TOPIC
Museum island on Spree river and Alexanderplatz TV tower in center of Berlin, Germany
Cancer
ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin
October 22, 2025
 · 
4 min read
 · 
Tristan Manalac
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Obesity
Terns Turns Away From Obesity Pill After ‘Uncompetitive’ Phase II Profile
October 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Human head with puzzle pieces and doodles vector illustration. Human brain lacking a piece of puzzle. Concept of brain function, memory loss, disorder, dementia. Abstract human head profile
Neuropsychiatric disorders
Alector Scraps Dementia Drug After Phase III Flop, Lays Off 49% of Staff
October 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Novo Board Upended, ESMO Excitement, FDA Awards, Replimune’s U-Turn
October 22, 2025
 · 
1 min read
 · 
Heather McKenzie